As the cannabis industry eyes international expansion, Europe is emerging as the next frontier. With the implementation of Germany’s Cannabis Act in April 2024, the continent’s largest economy has officially entered the legal cannabis era. For U.S. companies that missed early mover advantages in Canada, Germany offers a fresh opportunity to lead — but only for those who move with speed, precision, and local insight.

“Germany is the story,” says Rachel Wright, CEO of VERDANT Strategies “It’s the largest medical cannabis market in Europe, and with the recent reforms, it’s now the strategic entry point for U.S. operators looking to expand internationally.”

Why Germany First?

Germany’s cannabis reforms don’t mirror the U.S. retail-heavy model — and that’s exactly why it matters. Instead of commercial dispensaries, Germany has legalized personal use, home cultivation, and non-profit cannabis clubs with up to 500 members.

Meanwhile, its medical market remains robust and federally regulated, offering a clear path to revenue through pharmacy partnerships, import deals, and specialty product formulations.

According to industry analysts, Germany is expected to reach USD 85.6 million in market value by 2030, growing at a CAGR of 14.9%. With Europe projected to hit USD 7.25 billion by 2029, Germany is clearly the gateway to scalable cannabis business on the continent.

How U.S. Operators Can Succeed

Success in Europe demands strategic adaptation. What works in California won’t necessarily translate to Bavaria. U.S. companies must rethink their product positioning, compliance infrastructure, and market timing to meet European expectations.

For U.S. growers, direct exports to Germany are still off the table due to federal cannabis restrictions. The workaround? Partner with a Canadian licensed producer (LP) that holds EU-GMP certification and is authorized to export medical cannabis to Europe. This collaboration enables American cultivators to bring their genetics, cultivation expertise, and brand IP into the EU — without violating U.S. law.

“Teaming up with a Canadian LP gives U.S. growers a legal and strategic gateway to Europe,” says Rachel Wright, CEO of VERDANT Strategies. “But success hinges on how well you localize your financial and operational model for the European market.”

Wright, whose firm supports cannabis businesses across the U.S. and globally, emphasizes that a German market entry isn’t just about exports — it’s about building sustainable, compliant, and culturally relevant operations that align with EU regulations.

Whether through IP licensing, strategic joint ventures, or white-label partnerships, U.S. growers can gain exposure to Europe’s fast-growing medical market — but only by navigating the rules carefully and with the right partners.

What to Focus On: Strategic Niches for US Companies in general

Germany’s evolving framework opens key verticals for U.S. operators:

• EU-GMP or GACP-certified medical cannabis imports
  
  
• Home grow equipment tailored to individual cultivators and cannabis clubs
  
  
• GMP-compliant post-harvest processing and extraction technologies
  
  
• Localized cannabis software (compliance, traceability, club management)
  
  
• Club partnerships and branded education initiatives
  
  
• B2B financial and operational software tailored to German/EU rules

These entry points align well with the operational strengths of U.S. companies, particularly those with advanced tech, compliance, or manufacturing capabilities.

Tax, Entity & Structuring Insights

With Rachel Wright’s expertise in cross-border taxation and entity structuring, U.S. companies can take early action to prepare:

• Use an EU-based holding company (Ireland or Netherlands) for IP and tax optimization
  
  
• Set up a German operating subsidiary (GmbH) for market-facing activities
  
  
• Consider multi-entity structures to reduce risk and ensure compliance
  
  
• Plan for transfer pricing, cross-border VAT, and local employment tax obligations

Wright adds: “If you’re not building with scalability in mind, you’ll hit regulatory roadblocks. Smart structuring from day one is what separates the global players from those stuck in pilot mode.”

The Bottom Line

Germany is not a test market — it’s the proving ground for the next generation of global cannabis operators. Those who take a measured, strategic approach to entry will not only win in Germany but set themselves up for long-term success across the European continent.

By collaborating with experienced professionals like Rachel Wright and VERDANT Strategies, U.S. cannabis businesses can align their financial models, compliance systems, and expansion timelines to match the European market’s realities.

The European cannabis wave is real — and it begins in Berlin.

If you would like to learn more about entering the legal German cannabis market please click here.

About the Author